Antibodies
8 November 2011
Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint7 November 2011
Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American College of Allergy, Asthma & Immunology Meeting7 November 2011
Abbott Presents HUMIRA® (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis7 November 2011
Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid Arthritis7 November 2011
Health of Patients with Nonalcoholic Steatohepatitis Improved Through Treatment with Anti-CD3 Antibodies4 November 2011
FDA Approves U.S. Market Return for octagam® Following Octapharma’s Implementation of Enhanced Safety Measures2 November 2011
Immunomedics Announces FDA Allows Resumption of Clivatuzumab Tetraxetan Clinical Trial31 October 2011
Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors26 October 2011
Anthera Announces Last Patient Enrolled in PEARL-SC Study25 October 2011
MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States25 October 2011
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Lymphoma Malignancies24 October 2011
Thallion Pharmaceuticals Inc.: Blinded Results From Low Dose Cohort of Phase II SHIGATEC Trial Presented at IDSA Annual MeetingNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports